Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195391 | 0.94 | CYP1B1 (0.57) | CYP1B1ALDH1A1MAPTCYP3A4MAPK1 | |
| SCHEMBL3192344 | 0.91 | DYRK1A (0.51) | ALDH1A1MAPTDYRK1ADYRK1BKDM4E | |
| SCHEMBL3191685 | 0.88 | PARP1 (0.59) | CYP1B1ALDH1A1MAPTCYP3A4MAPK1 | |
| SCHEMBL3188202 | 0.85 | CYP1B1 (0.56) | CYP1B1ALDH1A1MAPTCYP3A4MAPK1 | |
| SCHEMBL3192458 | 0.83 | PDE5A (0.53) | ABCB1PARP1PARP2AKT1 | |
| SCHEMBL3184919 | 0.83 | PARP1 (0.57) | ABCB1PARP1PARP2AKT1 | |
| SCHEMBL3192814 | 0.82 | KDM4E (0.57) | MAPTKDM4EABCB1ABCG2GAA | |
| SCHEMBL8307616 | 0.81 | CYP1A1 (0.58) | CYP1B1DYRK1ADYRK1BKDM4ETERT | |
| SCHEMBL7379704 | 0.81 | DYRK1A (0.64) | CYP1B1ALDH1A1MAPTDYRK1ADYRK1B | |
| SCHEMBL8574988 | 0.79 | DYRK1A (0.50) | CYP1B1ALDH1A1MAPTCYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | claimed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | claimed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | claimed |
| CN-103965172-A | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-103965173-A | Compounds and methods for treating estrogen receptor-related disorders | HENOGEN PHARMA GROUP LTD | 2014-08-06 | — | — | CN | disclosed |
| CN-102018698-B | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-07-02 | — | — | CN | disclosed |
| CN-103755673-A | Compounds and methods for treating estrogen receptor-related disorders | SHENOGEN PHARMA GROUP LTD | 2014-04-30 | — | — | CN | disclosed |
| EP-2262366-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | Shenogen Pharma Group Ltd. (CN) | 2010-12-22 | — | — | EP | disclosed |
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| WO-2009129372-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | SHENOGEN PHARMA GROUP LTD. (CN) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016352-A1 | COMPOUNDS AND METHODS FOR TREATING ESTROGEN RECEPTOR-RELATED DISEASES | ESR2, ESR1, ESRRB | CYP1B1 2239/4885ALDH1A1 1811/4885MAPT 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.